Adamis Pharmaceuticals (NASDAQ:ADMP)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a research report issued on Wednesday, AnalystRatings.com reports. They presently have a $1.50 target price on the specialty pharmaceutical company’s stock. Maxim Group’s target price would indicate a potential upside of 93.00% from the stock’s previous close.
A number of other research analysts have also recently issued reports on the stock. Raymond James restated a “hold” rating on shares of Adamis Pharmaceuticals in a report on Wednesday, August 19th. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 25th. Finally, Dawson James cut shares of Adamis Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, August 24th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $1.08.
Shares of NASDAQ ADMP traded up $0.01 during trading on Wednesday, reaching $0.78. The company had a trading volume of 11,340 shares, compared to its average volume of 3,073,413. Adamis Pharmaceuticals has a 52 week low of $0.27 and a 52 week high of $1.51. The stock has a market cap of $56.92 million, a PE ratio of -1.58 and a beta of 2.16. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.80 and a current ratio of 0.97. The business’s 50 day moving average price is $0.87 and its 200-day moving average price is $0.62.
A hedge fund recently bought a new stake in Adamis Pharmaceuticals stock. Sabby Management LLC bought a new position in shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 88,210 shares of the specialty pharmaceutical company’s stock, valued at approximately $32,000. Sabby Management LLC owned about 0.12% of Adamis Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 6.91% of the company’s stock.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.